Search company, investor...

Predict your next investment

Angelini Pharma company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
angelinipharma.com

Investments

1

Partners & Customers

10

Service Providers

1

About Angelini Pharma

Angelini Pharma develops pharmaceuticals for mental health conditions, pain & inflammation, paediatric diseases, and consumer health. The company also partners with hospitals, research centers, pharma biotech, and CROs to favor innovation.

Headquarters Location

Viale Amelia 70

Roma, 00181,

Italy

+39 06 78053-1

Want to inform investors similar to Angelini Pharma about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Angelini Pharma News

SK Biopharmaceuticals’ epilepsy drug gets permit in France

Dec 15, 2022

SK Biopharmaceuticals’ epilepsy drug gets permit in France 바로가기 기자명 Lee Han-soo 닫기 SK Biopharmaceuticals said that Angelini Pharma, its EU partner, has won sales approval for cenobamate, an epilepsy drug, in France. SK Biopharmaceuticals' EU partner has won approval for Cenobamate in France and has now completed the approval process for the drug in all five major EU countries. The company initially launched cenobamate, under the product name Ontozry, in the EU market after obtaining sales approval from the European Commission in March last year. Angelini Pharma released Ontozry for the first time in Germany for the EU market in June last year. Afterward, within a year and a half, the company expanded cenobamate’s market share to the remaining four major European markets, including the U.K., Italy, Spain, and France. The size of the epilepsy market in the five major EU countries is about $1.7 billion, which corresponds to about 73 percent of the total epilepsy market in EU. Aside from the five major countries, the company is also marketing the treatment in 10 other EU countries. “With the expansion of sales in Europe through the approval of Ontozry in France, we expect to secure sales royalties and milestone revenue related to sales performance from Angelini Pharma,” an SK Biopharmaceuticals official said. Meanwhile, Cenobamate exceeded $100 million in exports to the U.S. and Europe from July 1, 2021, to June 30, 2022, and was awarded the “$100 million achievement award” during the 59th Day of Trade ceremony held on Monday. According to the company, it was the first time a Korean pharmaceutical company won the $100 million achievement award for a single locally-developed new drug. In the U.S., SK Biopharmaceutical received marketing approval for Cenobamate from the Food and Drug Administration (FDA) in 2019 and launched the product under the name Xcopri.

Angelini Pharma Investments

1 Investments

Angelini Pharma has made 1 investments. Their latest investment was in DAMONA Pharmaceuticals as part of their Seed VC on September 9, 2022.

CBI Logo

Angelini Pharma Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/26/2022

Seed VC

DAMONA Pharmaceuticals

$5.5M

Yes

1

Date

9/26/2022

Round

Seed VC

Company

DAMONA Pharmaceuticals

Amount

$5.5M

New?

Yes

Co-Investors

Sources

1

Angelini Pharma Acquisitions

4 Acquisitions

Angelini Pharma acquired 4 companies. Their latest acquisition was Arvelle Therapeutics on January 04, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/4/2021

Series A

$99M

$207.8M

Acquired

18

4/24/2020

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2020

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2021

4/24/2020

3/10/2020

3/9/2020

Investment Stage

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

$207.8M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

18

10

10

10

Angelini Pharma Partners & Customers

10 Partners and customers

Angelini Pharma has 10 strategic partners and customers. Angelini Pharma recently partnered with SK Biopharmaceuticals on December 12, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

12/8/2022

Licensor

South Korea

17:30 ET SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

Cenobamate was discovered by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science , which have forged a partnership with Angelini Pharma for the European markets .

2

3/10/2021

Vendor

United States

Angelini Pharma Chooses AiDEA’s Artificial Intelligence to Boost Its Digital Transformation and International Growth

VERONA , Italy -- -- Trueblue , a leading provider of AI solutions for Operational and Analytical CRM in the Life Science industry announces that Angelini Pharma , as part of a major global digital transformation process , has chosen AiDEA , the first AI-Digital Cloud Pharma CRM solution based on Microsoft 365 .

2

1/1/2021

Partner

Italy

Contributing to assess the impact of Covid-19 on mental health: our Headway Mental Health Index quoted as reference in EP policy brief

Headway is an initiative on Mental Health that was conceived and launched in 2017 by the think tank The European House Ambrosetti in partnership with Angelini Pharma with the aim of creating a multidisciplinary platform for strategic reflection , analysis , dialogue and comparison between various European experiences in the management of individuals affected by mental disorders .

1

7/26/2020

Vendor

United States

Subscribe to see more

Subscribe to see more

10

7/22/2020

Vendor

Subscribe to see more

Subscribe to see more

10

Date

12/8/2022

3/10/2021

1/1/2021

7/26/2020

7/22/2020

Type

Licensor

Vendor

Partner

Vendor

Vendor

Business Partner

Country

South Korea

United States

Italy

United States

News Snippet

17:30 ET SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France

Cenobamate was discovered by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science , which have forged a partnership with Angelini Pharma for the European markets .

Angelini Pharma Chooses AiDEA’s Artificial Intelligence to Boost Its Digital Transformation and International Growth

VERONA , Italy -- -- Trueblue , a leading provider of AI solutions for Operational and Analytical CRM in the Life Science industry announces that Angelini Pharma , as part of a major global digital transformation process , has chosen AiDEA , the first AI-Digital Cloud Pharma CRM solution based on Microsoft 365 .

Contributing to assess the impact of Covid-19 on mental health: our Headway Mental Health Index quoted as reference in EP policy brief

Headway is an initiative on Mental Health that was conceived and launched in 2017 by the think tank The European House Ambrosetti in partnership with Angelini Pharma with the aim of creating a multidisciplinary platform for strategic reflection , analysis , dialogue and comparison between various European experiences in the management of individuals affected by mental disorders .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

Angelini Pharma Service Providers

1 Service Provider

Angelini Pharma has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Counsel

General Counsel

Service Provider

Associated Rounds

Acquired

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Angelini Pharma Team

2 Team Members

Angelini Pharma has 2 team members, including current Chief Executive Officer, Pierluigi Antonelli.

Name

Work History

Title

Status

Pierluigi Antonelli

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Pierluigi Antonelli

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Status

Current

Subscribe to see more

Compare Angelini Pharma to Competitors

O
Otsuka America Pharmaceutical

Otsuka America Pharmaceutical (OAPI) researches, develops, manufactures, and markets pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health in North America. The company focuses on a portfolio of products in neuroscience, oncology, cardio-renal, and medical device markets. It offers pharmaceutical products, including tablets and injections or conditioning agents; and medical devices, including urea breathe test devices.

IAMA Therapeutics Logo
IAMA Therapeutics

IAMA Therapeutics is a pharmaceutical company that develops a platform to identify and advance diverse classes of small molecules to selectively inhibit the sodium potassium chloride cotransporter and other therapeutic targets relevant to treating central nervous system disorders characterized by neuronal imbalance, including primary and secondary autism, epilepsy, and movement disorders.

Ovid Therapeutics Logo
Ovid Therapeutics

Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine approach to develop therapies that transform the lives of patients with rare neurological diseases. Ovid's lead product candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.

SAGE Therapeutics Logo
SAGE Therapeutics

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat rare and orphan diseases of the central nervous system (CNS). SAGE's lead program, SAGE-547, is in clinical development for super refractory status epilepticus and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. In addition to status epilepticus, the company's initial pipeline includes programs in neuroanesthesia and orphan genetic CNS disorders where currently available therapies poorly address the areas of most urgent patient need and may also be accompanied by considerable side effects. SAGE's robust allosteric modulator chemistry platform has generated multiple new compounds that target the GABAA and NMDA pathways, which have demonstrated preclinical activity.

P
Praxis Precision Medicines

Praxis Precision Medicines (NASDAQ: PRAX) is a clinical-stage genetic neuroscience company developing breakthrough therapies for patients and families affected by complex and debilitating brain disorders, including psychiatric disorders, movement disorders and rare pediatric epilepsies. These disease areas share overlapping genetics and neurocircuit biology, as well as a profound need for new therapeutic options that target the underlying cause of the disease. Praxis is advancing a pipeline of breakthrough medicines with the potential to more precisely treat brain disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.